Physician profile
Hassan Yousaf
NPI 1851754170
$97,312.86
in general payments reported to CMS, 2019-2025
31 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.36 · 2022: $270 · 2023: $684 · 2024: $11K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $12K · Travel and Lodging: $9,917 · Education: $8,081 · Food and Beverage: $5,740 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,120.00 |
| Consulting Fee | $12,135.17 |
| Travel and Lodging | $9,916.73 |
| Education | $8,080.86 |
| Food and Beverage | $5,739.92 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44,923.85 | 2024-2025 | |
| Glaxosmithkline, LLC. | $14,271.43 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $12,750.86 | 2023-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,838.89 | 2023-2025 | Ofev, Jascayd |
| Intuitive Surgical, INC. | $9,295.15 | 2024-2025 | |
| Chiesi USA, INC. | $2,421.28 | 2025 | |
| United Therapeutics Corporation | $336.92 | 2022-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $311.80 | 2022-2025 | Acthar |
| Mylan Specialty L.P. | $216.03 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $206.35 | 2023-2025 | Dupixent |
| Insmed, INC. | $91.91 | 2023-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $87.92 | 2022-2024 | Glassia |
| Verona Pharma, INC. | $64.06 | 2025 | Ohtuvayre |
| Baxter Healthcare | $63.68 | 2024-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Grifols USA, LLC | $59.79 | 2024-2025 | Prolastin-C Liquid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.03 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $45.52 | 2023-2024 | Uptravi, Opsumit |
| Viatris Specialty LLC | $38.34 | 2025 | Yupelri |
| Amgen INC. | $35.10 | 2024-2025 | Tezspire, Tavneos |
| Csl Behring | $24.76 | 2024 | Hizentra |
| Shionogi INC | $24.24 | 2022 | |
| Tempus Ai, INC | $22.68 | 2025 | Xt Cdx |
| Tactile Systems Technology INC | $19.96 | 2022 | |
| Bard Peripheral Vascular, INC. | $18.62 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $17.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.32 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $15.93 | 2025 | Lumryz |
| Alexion Pharmaceuticals, INC. | $15.48 | 2019 | |
| Pfizer INC. | $15.44 | 2023 | |
| Electromed, INC. | $14.64 | 2024 | Smartvest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Yousaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.